EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tectonic Therapeutic's enterprise value is $109.33 Mil.
Tectonic Therapeutic's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-56.94 Mil. Therefore, Tectonic Therapeutic's EV-to-EBITDA for today is -1.92.
The historical rank and industry rank for Tectonic Therapeutic's EV-to-EBITDA or its related term are showing as below:
TECX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.07 Med: 0 Max: 0
Current: -1.92
TECX's EV-to-EBITDA is ranked worse than 100% of 501
companies
in the Biotechnology industry
Industry Median: 7.89
vs TECX: -1.92
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Tectonic Therapeutic EV-to-EBITDA Historical Data
The historical data trend for Tectonic Therapeutic's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tectonic Therapeutic's EV-to-EBITDA
For the Biotechnology subindustry, Tectonic Therapeutic's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tectonic Therapeutic's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tectonic Therapeutic's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tectonic Therapeutic's EV-to-EBITDA falls into.
Tectonic Therapeutic's current Enterprise Value is $109.33 Mil.
Tectonic Therapeutic's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tectonic Therapeutic's PE Ratio (TTM) for today is calculated as:
Tectonic Therapeutic's share price for today is $21.605.
Tectonic Therapeutic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.830.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Tectonic Therapeutic's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TECX has been successfully added to your 